Abstract 469P
Background
The advancements in treatment strategies for cancer in Adolescent and Young Adults (AYAs) and early diagnosis has led to an increase in the cure rate and an increase in the number of AYA cancer survivors. The AYA patient is defined as an individual 15 to 39 years of age at the time of initial cancer diagnosis. AYA cancer survivors are at increased risk of developing various physical and psychosocial issues which vary from those in older adults. There are very few integrated survivorship programmes for AYA cancer survivors in India and this is a huge unmet need.
Methods
This online survey was directed at oncologists from various major specialties in India, with an interest in the care of AYA cancer patients and survivors. Oncologists practicing in India were sent the survey questionnaire through Google link via e-mail. Data was collected in SPSS and descriptive statistics were performed.
Results
We received 100 responses from June 2021 to September 2021 from oncologists all over India. 85% of respondents were medical oncologists, with 59% working at academic centers. Among oncologists who responded to this survey, 74% reported that AYA cancer survivors comprised ≤ 25% of their clinical practice. Major issues faced by most of the survivors included fatigue, anxiety, depression, fear of recurrence, and financial and social issues. Although 88% of the respondents reported the need for a separate follow-up clinic for AYA survivors, only 32% had a dedicated cancer survivor clinic or program at their center. Half of these oncologists had a team of multidisciplinary care providers in their clinic. 58% of the respondents reported that more than 50% of the survivors have resumed their normal life.
Conclusions
There is an unmet need for specialized care for AYA cancer survivors in India. Only 32% of oncologists have dedicated clinics for AYA cancer survivors. There is a need to develop survivorship programs for AYA survivors across the country.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract